Back to Search
Start Over
Recombinant proteins production in Escherichia coli BL21 for vaccine applications: a cost estimation of potential industrial-scale production scenarios.
- Source :
-
Preparative biochemistry & biotechnology [Prep Biochem Biotechnol] 2024 Aug; Vol. 54 (7), pp. 932-945. Date of Electronic Publication: 2024 Jan 10. - Publication Year :
- 2024
-
Abstract
- Recent SARS-CoV-2 pandemic elevated research interest in microorganism-related diseases, and protective health application importance such as vaccination and immune promoter agents emerged. Among the production methods for proteins, recombinant technology is an efficient alternative and frequently preferred method. However, since the production and purification processes vary due to the protein nature, the effect of these differences on the cost remains ambiguous. In this study, brucellosis and its two important vaccine candidate proteins (rOmp25 and rEipB) with different properties were selected as models, and industrial-scale production processes were compared with the SuperPro Designer <superscript>®</superscript> for estimating the unit production cost. Simulation study showed raw material cost by roughly 60% was one of the barriers to lower-cost production and 52.5 and 559.8 $/g were estimated for rEipB and rOmp25, respectively.
- Subjects :
- SARS-CoV-2 genetics
SARS-CoV-2 immunology
COVID-19 prevention & control
Humans
COVID-19 Vaccines immunology
COVID-19 Vaccines economics
COVID-19 Vaccines genetics
Industrial Microbiology methods
Industrial Microbiology economics
Recombinant Proteins genetics
Recombinant Proteins biosynthesis
Escherichia coli genetics
Escherichia coli metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1532-2297
- Volume :
- 54
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Preparative biochemistry & biotechnology
- Publication Type :
- Academic Journal
- Accession number :
- 38198230
- Full Text :
- https://doi.org/10.1080/10826068.2023.2299495